Predict your next investment

Venture Capital
hbmhealthcare.com

See what CB Insights has to offer

Investments

198

Portfolio Exits

69

About HBM Healthcare Investments

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of some twenty five promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

HBM Healthcare Investments Headquarter Location

Bundesplatz 1

Zug, CH-6300,

Switzerland

41 41 768 11 08

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest HBM Healthcare Investments News

Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New...

Jun 17, 2022

– Momentum continues to build for Dren Bio after successfully forming highly experienced senior leadership team and earlier this year announcing research collaboration and license deal with Pfizer  – The financing round was co-led by Aisling Capital and HBM Healthcare Investments with participation from new investors Pfizer, ArrowMark Partners and Revelation Partners, along with all current insiders FOSTER CITY, CA – June 14, 2022 – Dren Bio, Inc. (“Dren Bio” or the “Company”) today announced the completion of their $65 million Series B financing, pushing the Company’s total capital received to date over $156 million. Following the financing, Dren Bio is well-capitalized to reach multiple key inflection points across both its drug discovery programs over the coming years.“We are truly grateful for all the support we continue to receive from such an outstanding syndicate of investors,” said Nenad Tomasevic, Ph.D., Chief Executive Officer of Dren Bio. “This financing comes at the perfect time as we prepare to initiate the first clinical trial evaluating DR-01, our lead asset, in patients with Large Granular Lymphocytic leukemia or cytotoxic lymphomas in mid-2022. In addition to advancing DR-01, the proceeds from this latest round will also enable us to further expand the development of our internal pipeline using our proprietary Targeted Myeloid Engager and Phagocytosis Platform.”The Series B financing was co-led by Aisling Capital and HBM Healthcare Investments, with participation by new marquee investors Pfizer, ArrowMark Partners and Revelation Partners. There was also significant participation in the round by Dren Bio’s existing insiders SR One, 8VC, Taiho Ventures, BVF PartneOKrs, Mission BioCapital and Alexandria Venture Investments, amongst others. In connection with the closing of the financing, the Company announced that Andrew Schiff, M.D., of Aisling Capital, and Chandra P. Leo, M.D., of HBM Partners, will join its Board of Directors.“We were thoroughly impressed by Dren Bio’s diversified R&D portfolio that encompasses two distinct therapeutic antibody programs including their attractive proprietary platform,” said Dr. Schiff, Managing Partner at Aisling Capital. “We are excited by the opportunity to support Dren Bio in progressing on their mission to deliver revolutionary therapies to patients with severe unmet needs, starting with difficult-to-treat cancers.”

HBM Healthcare Investments Investments

198 Investments

HBM Healthcare Investments has made 198 investments. Their latest investment was in Mineralys Therapeutics as part of their Series B on June 6, 2022.

CBI Logo

HBM Healthcare Investments Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/8/2022

Series B

Mineralys Therapeutics

$118M

No

6

6/2/2022

Series A

Upstream Bio

$200M

Yes

2

3/29/2022

Series B

Dren Bio

$65M

No

1

3/28/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

2/7/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/8/2022

6/2/2022

3/29/2022

3/28/2022

2/7/2022

Round

Series B

Series A

Series B

Series B

Series A

Company

Mineralys Therapeutics

Upstream Bio

Dren Bio

Subscribe to see more

Subscribe to see more

Amount

$118M

$200M

$65M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

2

1

10

10

HBM Healthcare Investments Portfolio Exits

69 Portfolio Exits

HBM Healthcare Investments has 69 portfolio exits. Their latest portfolio exit was Arena Pharmaceuticals on December 13, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/13/2021

Acq - P2P

$99M

5

11/5/2021

IPO

$99M

Public

12

10/8/2021

IPO

$99M

Public

9

6/24/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/18/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/13/2021

11/5/2021

10/8/2021

6/24/2021

6/18/2021

Exit

Acq - P2P

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

5

12

9

10

10

HBM Healthcare Investments Team

2 Team Members

HBM Healthcare Investments has 2 team members, including current Chief Executive Officer, Andreas Wicki.

Name

Work History

Title

Status

Andreas Wicki

Chief Executive Officer

Current

Erwin Troxler

Chief Financial Officer

Current

Name

Andreas Wicki

Erwin Troxler

Work History

Title

Chief Executive Officer

Chief Financial Officer

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.